Pharmac Notification

Kia ora Pharmac has decided to fund another brand of methylphenidate, Rubifen LA, to help ease supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD).  Rubifen LA will be funded from 1 October 2026.

• Decision to fund a new brand of methylphenidate

  
  

Thank you to everyone who provided feedback during consultation. This feedback has informed our decision.

If you have any questions, please contact us at enquiry@pharmac.govt.nz. 

Ngā mihi nui,

Pharmac | Te Pātaka Whaioranga | P: +0800 660 050| www.pharmac.govt.nz